Evercore, goetzpartners and Cooley LLP acted as advisors to Autolus.
About BioNTech’s Portfolio of Cell and Gene TherapiesBioNTech has been active in the progression of mobile and gene therapies since 2009. Today, it is a core generation platform in BioNTech’s portfolio. BioNTech’s portfolio of synthetic mobile therapeutics includes chimeric antigen receptor (CAR) and T-mobile receptor (TCR) or individualized curative drug applicants for T-mobile receptors.
BNT211 is BioNTech’s highest complexity mobile treatment progression program. BNT211 is an autologous mobile CAR-T treatment candidate from Claudin-6 (CLDN6) that is being tested alone and in admixture with a mobile CAR-T enhancing RNA vaccine (“CARVac”). CLDN6 encoding. CAR-T mobiles are supplied with a second generation CAR with maximum sensitivity and specificity. CARVac is intended for the in vivo expansion of CAR-T mobiles to increase their patience and efficiency. CLDN6 is expressed in various falsified tumors such as ovarian cancer, sarcoma, testicular cancer, endometrial cancer and gastric cancer. BioNTech plans to initiate its first pivotal Phase 2 trial comparing BNT211 in 2L mobile germ cell tumors in 2024 and continues to compare additional indications for further progression.
About BioNTech BioNTech is a next-generation immunotherapy company pioneering cutting-edge treatments for cancer and other serious diseases. BioNTech leverages a wide diversity of computational discovery platforms and curative drugs for the immediate progression of new biopharmaceuticals. Its broad portfolio of oncology product applicants includes individualized products. and commercially available mRNA-based treatments, cutting-edge chimeric antigen receptor (CAR) T cells, protein-based therapeutics that add bispecific immune checkpoint modulators, targeted cancer antibodies, and antibody-drug conjugates (ADCs), as well as small molecules. . Drawing on its deep expertise in mRNA vaccine progression and in-house production capabilities, BioNTech and its collaborators are submitting applicants for mRNA vaccines for a variety of infectious diseases, across its diverse oncology portfolio. BioNTech has established a wide variety of relationships with a number of global companies. pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Roche Group member Genentech, Genevant, Genmab, OncoC4, Regeneron and Pfizer. For more information, visit www. BioNTech. com.
Please review the hazards and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended September 30, 2023, as well as in BioNTech’s upcoming filings with the SEC, found on the SEC’s website. website. Except as required by law, BioNTech disclaims any objective or duty to update or revise any forward-looking statements contained in this press release, whether as a result of new information, long-term developments or otherwise. These forward-looking statements are based on BioNTech’s existing expectations and speak only as of the date hereof.
About Autolus Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Autolus Forward-Looking Statements This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not past facts and, in certain cases, are can know the matrix. through terms such as “possibly”, “may”, “may also”, “expects”, “plans”, “anticipates” and “believes”. These statements include, but are not limited to, statements relating to Autolus’ progression of its product applicants, adding the obe-cel program; the profile and prospective application of obe-cel in other pathological contexts; Long-term clinical progression, efficacy, protection and prospective cure of Autolus product applicants, aggregating progress, knowledge, behavior and time reporting expectations, and prospective long-term clinical and preclinical activity and milestones; expectations related to the initiation, design and reporting of knowledge from clinical trials and preclinical studies; expectations related to the regulatory approval procedure for any product candidate; the benefits of the collaboration between Autolus and BioNTech, including the prospect and timing of receipt of equity investments, milestone bills, profit sharing bills and/or royalties under the terms of the strategic collaboration; Autolus’ existing and long-term production capabilities; and the final touch and timing of the proposed personal placement. All forward-looking statements are based on management’s existing ideals and assumptions and involve dangers and uncertainties that may also cause actual effects, functionality or occasions to differ materially from those expressed or implied by such statements. These dangers and insecurities include, but are not limited to, the dangers that Autolus’ preclinical or clinical systems may not progress or result in approved products in a timely or cost-effective manner, or at all; The effects of early clinical trials do not always predict long-term results; the cost, timing and effects of clinical trials; that many product applicants are not converted to approved medicines in a timely manner or cost-effectively, if at all; the ability to enroll patients in clinical trials; and imaginable problems of protection and effectiveness. For a discussion of other dangers and uncertainties, as well as other vital points, any of which may also cause Autolus’ actual effects to differ from those contained in the forward-looking statements, please see the segment titled “Risk Factors” in the Annual Report. of Autolus on Form 20-F filed with the Securities and Exchange Commission, or SEC, on March 7, 2023 and in Autolus’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on March 9, 2023. November 2023, as well as discussions of conceivable dangers, insecurities and other vital points in Autolus’ upcoming filings with the Securities and Exchange Commission. All data contained in this press release is as of the date of publication and Autolus undertakes no legal responsibility to publicly update any future information. forward-looking statement, whether as a result of new data, long-term occasions or otherwise, unless required by law. Therefore, you should not rely on such forward-looking statements as representing Autolus’ prospects as of any date after this date. of this press release.
Contacts:
Media Relations Jasmina Alatovic (0)6131 9084 1513 Media@biontech. de
Autolus Olivia Manser +44 (0) 7780 [email protected]
Julia Wilson +44 (0) 7818 430877 [email protected] Susan A. Noonan S.A. Noonan Communications +1-917-513-5303 [email protected]